Calumet, Inc - Common Stock (CLMT)

In a series of strategic maneuvers that have caught the attention of mid-cap investors, Alta Fundamental Advisers has significantly reshaped its portfolio as of late 2025. The New York-based hedge fund, known for its deep-value approach and focus on special situations, has completely liquidated its position in Calumet, Inc. (NASDAQ:

Calumet just posted eye-catching profits, but one fund still headed for the exits.

Calumet's profitable again, but is it a buy?

Calumet (CLMT) posted a Q3 2025 loss of $0.21 per share, beating estimates. Revenue was in line. The stock saw a muted positive reaction.

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

Calumet Inc (CLMT) reports Q2 2025 loss of $1.70 per share, missing estimates despite revenue beat. Shares drop amid investor concerns over profitability.

Calumet shares rise after analyst highlights MaxSAF-driven EBITDA growth and debt reduction potential.

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Shares of Calumet and Gevo are on the move in extended trading Wednesday after the companies received conditional commitments from the U.S. Department of Energy (DOE).

CLMT stock results show that Calumet Specialty Prods beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

These hydrogen stock picks are boasting improving financials that even Wall Street can't deny. Check them out now!